AMS IS THE INDUSTRY LEADER IN STRATEGIC INTELLIGENCE SOFTWARE FOR COMBATTING EMERGING HIGH-COST CLAIM ISSUES
What We Do:
AMS delivers crucial insight into catastrophic diagnoses, specialty pharmaceutical, and implant price transparency through clinically vetted, predictive financial analytics with near real-time data.
Who We Serve:
AMS serves multiple stakeholders in the medical claims payment chain, including commercial and governmental payers, Stop Loss and Reinsurance Carriers, MGUs, Medical Management Firms, Health Plans, TPAs, HMOs, Taft-Hartley Plans, workers compensation, and auto medical carriers.
WHO IS USING THE PREDICT SUITE
THE PREDICT SUITE
AMS’ Web-based directories that allow
clients to predict, evaluate and manage high dollar healthcare claims.
PREDICT
Predict costs and clinical treatments for high dollar diagnoses with an on demand decision support solution delivering in-depth clinical information, empirical insight and key financial analytics.
EVALUATE
Evaluate cost data, FDA approved indications, notable off-label usage, adult/pediatric dosing regimens, manufacturer rebates, specialty drug coding and price trends.
MANAGE
Manage highly inflated implant claims by leveraging detailed clinical and financial metrics with the only online, fully- transparent implant cost directory in the industry.
PREDICT SUITE MEMBERSHIP HAS ITS BENEFITS
100%
Reference Rate
Predict Suite Members willing + eager to connect with prospects
99%
Members
Retained
We have retained 99% of our members
13,000
Clinical/Financial Iterations
Including rules, off label + orphan drug uses, price benchmarks and CPT codes
100s
Weekly Hours
Saved
We have saved our clients and members 100s of weekly hours in research and underwriting
AMS Blog
-
A simple pop-up alert on a computer screen could help save the brains and hearts of many hospital-bound people with an irregular heartbeat, a new clinical trial reveals. Rates for heart attack and stroke plunged by close to 90 percent in people helped by the new program, the study found. The computer alert warns doctors… Read More »
-
The FDA has granted a fast track designation to selinexor for the treatment of patients with previously treated diffuse large B-cell lymphoma (DLBCL) who are ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor (CAR) T-cell therapy, according to Karyopharm Therapeutics, Inc., the manufacturer of the first-in-class SINE compound.1 The designation… Read More »